Bristol Myers Squibb’s Krazati failed its confirmatory trial in second-line colorectal cancer, according to the company’s spokesperson. The result puts the drug’s accelerated approval status in jeopardy because confirmatory study outcomes are used to determine whether approvals are converted to full indications. Krazati received accelerated approval in 2024 for the second-line setting, and the latest failure creates uncertainty for patients and for ongoing market access decisions. The report also raises the stakes for continued trial enrollment and for competing therapies targeting similar pathways. For BMS and other sponsors operating under accelerated-approval frameworks, the development is a reminder of how quickly confirmatory outcomes can reshape portfolios and regulatory plans.